PMID: 9190976Jun 1, 1997Paper

Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study

Gynecologic Oncology
Ch KurzP Sevelda

Abstract

In order to examine the influence of erythropoietin (rHuEPO) on serum hemoglobin levels, transfusion requirements, and quality of life in patients with gynecologic malignancies under polychemotherapy and chronic tumor anemia (hemoglobin <11 g/dl), we performed a prospective, randomized, double-blinded placebo-controlled clinical trial. Between October 1992 and October 1993, 35 patients from 5 gynecologic departments were entered into this trial. Inclusion criteria were hemoglobin level <11 g/dl, ferritin level >29 ng/ml, stool negative for occult blood, and life expectancy for more than 3 months. Patients received either 150 U/kg body wt rHuEPO (Erypo by Cilag-Janssen) sc three times a week for 12 weeks (n = 23) or a placebo (n = 12). If the hemoglobin levels of the 4th, 8th, or 12th week were >2 g/dl above the baseline value and/or >12 g/dl, the patient was classified as a responder. Patients who required blood transfusions (hemoglobin <8 g/dl, erythrocytes <3 x 10(6)/ml, or clinical symptoms of anemia) were classified as nonresponders. A nonvalidated quality of life questionnaire was completed by the patient at the beginning of the treatment and then every fourth week before receiving chemotherapy. In the rHuEPO group 56.6% o...Continue Reading

Citations

Mar 21, 2002·The Lancet Oncology·Andrew BottomleyBenjamin Djulbegovic
Nov 28, 2001·Hematology·J D RizzoT J Littlewood
May 18, 2006·Journal of the National Cancer Institute·Julia BohliusAndreas Engert
Mar 30, 2006·British Journal of Cancer·P M WilkinsonUNKNOWN EPO-INT-45 Study Group
Dec 14, 2012·The Cochrane Database of Systematic Reviews·Thomy ToniaJulia Bohlius
Sep 25, 2002·BMC Cancer·Otavio ClarkBenjamin Djulbegovic
Apr 7, 2005·Journal of the National Cancer Institute·Julia BohliusAndreas Engert
Feb 19, 2008·Expert Review of Anticancer Therapy·Dana M ChaseKrishnansu S Tewari
Nov 18, 2009·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Vicente Alberola CandelUNKNOWN Spanish Society of Medical Oncology
Oct 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter NieboerElisabeth G E de Vries
Aug 10, 2000·Drugs & Aging·R E van Rijswijk, J B Vermorken
Jul 10, 2009·The Cochrane Database of Systematic Reviews·Julia BohliusAndreas Engert
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Douglas RizzoUNKNOWN American Society of Clinical Oncology. American Society of Hematology
Dec 1, 2001·Journal of Pain and Symptom Management·R TurnerUNKNOWN Canadian Cancer and Anemia Guidelines Development Group
Jun 17, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Engert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.